Company Description
Seelos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of central nervous system and other disorders.
The company’s lead programs are SLS-002, an intranasal racemic ketamine for the treatment of acute suicidal ideation and behavior in patients with major depressive disorders; SLS-004, an gene therapy targeting gene and alpha synuclein; SLS-005, a protein stabilizer for the treatment of amyotrophic lateral sclerosis and Sanfilippo syndrome; SLS-007, a peptidic inhibitor for NACore Parkinson disease; and SLS-009, a protein targeted autophagy for Alzheimer disease.
Seelos Therapeutics, Inc. was founded in 2016 and is headquartered in New York, New York.
| Country | United States |
| Founded | 2016 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 16 |
| CEO | Dr. Raj Mehra J.D., Ph.D. |
Contact Details
Address: 300 Park Avenue, 2nd Floor New York, New York 10022 United States | |
| Phone | (646) 293-2100 |
| Website | seelostherapeutics.com |
Stock Details
| Ticker Symbol | SEEL |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001017491 |
| CUSIP Number | 81577F109 |
| ISIN Number | US81577F2083 |
| Employer ID | 87-0449967 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Raj Mehra J.D., Ph.D. | Founder, Chairman, Chief Executive Officer and President |
| Michael J. Golembiewski | Chief Financial Officer |
| Kimberly Farrand | Senior Director of Clinical Development and Operations |
| Anthony Marciano | Chief Communications Officer |
| Gopal Krishna Ph.D. | Head of Manufacturing and Technical Operations |
| Tim Whitaker M.D. | Chief Medical Officer |
| Karen Fusaro | Senior Vice President and Head of Clinical Operations |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jul 16, 2024 | 8-K | Current Report |
| Jul 12, 2024 | 8-K | Current Report |
| Jun 25, 2024 | EFFECT | Notice of Effectiveness |
| Jun 25, 2024 | 424B3 | Prospectus |
| Jun 14, 2024 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Jun 5, 2024 | 8-K | Current Report |
| May 31, 2024 | D | Notice of Exempt Offering of Securities |
| May 21, 2024 | 8-K | Current Report |
| May 20, 2024 | 424B5 | Filing |
| May 16, 2024 | 8-K | Current Report |